We have advised Orano, a French multinational nuclear fuel cycle corporation, on the acquisition, through its subsidiary Orano Projets, of a majority stake in Ceris Group to develop its activities in the healthcare, pharmaceuticals, and biotechnology sectors.
Specialising in engineering and consulting services, Ceris Group is organised by a business line around three subsidiaries: Ceris Ingénierie, Elix, and Ceris Architecture. These subsidiaries support their customers in sectors including pharmaceuticals and biotechnology, hospitals and nuclear medicine, as well as laboratories and other industries subject to severe constraints or highly controlled environments (microelectronics, cosmetics, etc.). Ceris Group employs around 50 people in France.
This acquisition will enable Orano Projets to accelerate the development of complementary know-how and new locations, in particular in Nantes and Lyon where Ceris Group is already established. Orano Projets will also benefit from a broadened product and service offering in the field of engineering, design and construction for industrial projects in the healthcare-pharmaceuticals and biotechnology sectors.
Orano Projets, with its 1,600 employees worldwide, will strengthen Ceris Group's capacity to respond to its customers' large-scale projects, whether for design and construction phases, service provision or complete turnkey projects.
